Brief: Active Biotech Releases Tasquinimod Study Results For RRMM
09/06/2025 15:55
June 9 (Reuters) - Active Biotech AB publ ACTI.ST: RELEASES TASQUINIMOD STUDY RESULTS FOR RRMM TASQUINIMOD WELL TOLERATED IN COMBINATION WITH IRD 47% CLINICAL BENEFIT RATE IN TOTAL COMBINATION COHORT Source text: ID:nMFN41wW5T Further company coverage: ACTI.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))